lysine has been researched along with rgfp966 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Brown, M; Cejas, P; Fisher, DE; Ito, Y; Kim, HJ; Long, HW; Meyer, CA; Olawoyin, O; Tay, RE; Weng, QY; Wucherpfennig, KW; Xie, Y | 1 |
2 other study(ies) available for lysine and rgfp966
| Article | Year |
|---|---|
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Hdac3 is an epigenetic inhibitor of the cytotoxicity program in CD8 T cells.
Topics: Acetylation; Acrylamides; Animals; Antigens; Base Sequence; CD8-Positive T-Lymphocytes; Core Binding Factor Alpha 3 Subunit; Epigenesis, Genetic; Histone Deacetylase Inhibitors; Histone Deacetylases; Histones; Lymph Nodes; Lymphocyte Activation; Lymphocytic choriomeningitis virus; Lysine; Mice, Inbred C57BL; Mice, Knockout; Phenotype; Phenylenediamines; Positive Regulatory Domain I-Binding Factor 1; T-Lymphocytes, Cytotoxic; Transcription, Genetic | 2020 |